A Pilot Study of Oxaloacetate in Subjects With Treated PD

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.

Key facts

Study ID

NCT01741701

Run by

University of Kansas Medical Center

People needed

33

Starts

2012-12-01

Expected to finish

2014-10-01

Last updated by the study team

2016-03-17

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to give informed consent and follow instructions per the protocol
• Diagnosis of idiopathic PD within 7 years of diagnosis
• Taking stable doses of levodopa and would not predictably need adjustment in PD medications for 4 months
• Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at baseline

You may not qualify if…

• Previously taken Oxaloacetate
• Participation in other drug studies or use of other investigational products within 30 days prior to baseline
• In the Investigator's opinion, any unstable or clinically significant condition that would impair the subjects' ability to comply with study follow-up
• Other known or suspected cause of parkinsonism

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.